GlobeNewsWire
19 Oct 2026, 05:30 UTC · 2h ago
Impact · against what's priced in
Telix and IBA are expanding their capabilities in alpha-emitting radioisotope production through a U.S.-based collaboration. This provides a strategic advantage in securing a scalable supply of astatine-211 for targeted alpha therapies.
No priced-in read yet
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Telix Pharmaceuticals and Ekalia announced a collaboration to advance scalable U.S. production of the alpha-emitting radioisotope astatine-211.
Newannounced today, Oct. 19, 2026
More positive than 94% of claims this week
Which stocks this story touches
Continue reading
5 related stories
IBA, via its joint venture Ekalia, is partnering with Telix to scale the production of medical isotopes in the United States.
Read from the article alone
No priced-in read yet
Telix is collaborating with Ekalia to establish scalable U.S. production of astatine-211, a key isotope for targeted alpha therapy.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 79% of ticker scores this week
IBA is a partner in the joint venture collaborating to scale medical isotope production.
More positive than 79% of ticker scores this week
Telix announced a collaboration to advance scalable U.S. production of a key radioisotope for therapy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
—
No price for IBA right now — the quote feed didn't answer.
IBA chart →—
TLX hasn't traded since this ran. Last close $10.69 (Oct 16); the reaction starts at the next open.
TLX chart →
